Publications by authors named "Elizabeth E Hanchrow"
Purpose: This study introduces an integrated approach using structured and unstructured data from an electronic health record to identify and characterize patient utilization of hereditary cancer genetic testing among patients with metastatic castration-resistant prostate cancer (mCRPC). Secondary objectives were to describe factors associated with the receipt of testing.
Methods: This retrospective cohort study included a cohort of Veterans diagnosed with mCRPC from January 2016 to December 2021.
Article Synopsis
- This study compares the cardiovascular effectiveness of different second-line antihyperglycemic agents (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas) in patients with type 2 diabetes and cardiovascular disease.
- Using data from over 1.4 million patients across multiple databases, the researchers analyzed the risk of major adverse cardiovascular events (MACE) over a follow-up period of several years.
- Results indicated that SGLT2 inhibitors and GLP-1 receptor agonists had significantly lower risks of MACE compared to DPP-4 inhibitors and sulfonylureas, pointing to their potential superiority as treatment options for
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study.
Rohan Khera Arya Aminorroaya Lovedeep Singh Dhingra Phyllis M Thangaraj Aline Pedroso Camargos Elizabeth E Hanchrow
medRxiv
February 2024
Article Synopsis
- * The study analyzed data from over 1.4 million patients treated with various second-line diabetes medications, using advanced statistical methods to compare outcomes and risks of heart issues.
- * Findings indicated that both SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of cardiovascular events compared to DPP-4 inhibitors and sulfonylureas, but no significant differences were found between SGLT2is and GLP1-RAs themselves regarding heart risks.
Article Synopsis
- The study aimed to evaluate the adoption of second-line antihyperglycaemic medications among type 2 diabetes patients using metformin, analyzing data from 10 US and 7 international health databases.
- A total of 4.8 million participants were included, focusing on the trends in initiating additional diabetes treatments over the years 2011 to 2021.
- Results showed significant growth in the use of cardioprotective drugs (like GLP-1 receptor agonists and SGLT2 inhibitors) as second-line options, with initiation rates varying widely across countries and databases.